Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Atai Life Sciences N.V. (NQ: ATAI )

15.68 USD -0.32 (-2.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 230,530
Open 15.90
Bid (Size) 15.40 (5)
Ask (Size) 16.00 (1)
Prev. Close 16.00
Today's Range 15.36 - 16.15
52wk Range 13.13 - 22.91
Shares Outstanding N/A
Dividend Yield 38.27%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases
NetworkNewsWire Editorial Coverage 
From PR Newswire
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder
From GlobeNewswire News Releases

Performance

YTD
-19.38%
-19.38%
1 Month
-1.57%
-1.57%
3 Month
-14.46%
-14.46%
6 Month
-19.38%
-19.38%
1 Year
-19.38%
-19.38%

More News

Read More
$10 Billion Sackler Opioid Settlement Closes Chapter, Psychedelic Chapter Begins
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
$10 Billion Sackler Opioid Settlement Closes Chapter, Psychedelic Chapter Begins
From PR Newswire
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data
From GlobeNewswire News Releases
Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases
From InvestorBrandNetwork
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
From GlobeNewswire News Releases
atai Life Sciences to Participate in Upcoming September Investor Conferences
From GlobeNewswire News Releases
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
Tags Cannabis ATAI MNMD
From Benzinga
Can Ibogaine Treat Opioid Addiction? Nasdaq-Listed Atai Is Launching A Trial To Find Out
Tags DemeRx IB Cannabis ATAI
From Benzinga
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial
Tags Market News Markets psychedelics
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]